周五，Teladoc Health(TDOC.US)股价走高，截至发稿，该股涨超9%，报9.398美元。多家华尔街大行更 新了Teladoc Health的评级，目标价介于9美元至12美元。其中，美银证券分析师Allen Lutz维持持有评 级，并将目标价从8.5美元上调至9美元。 ...

智通财经APP获悉，周五，Teladoc Health(TDOC.US)股价走高，截至发稿，该股涨超9%，报9.398美 元。多家华尔街大行更新了Teladoc Health的评级，目标价介于9美元至12美元。其中，美银证券分析师 Allen Lutz维持持有评级，并将目标价从8.5美元上调至9美元。 ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Teladoc Health CFO Mala Murthy is stepping down from her role effective Nov. 21, the telehealth company said Thursday. Murthy, who has served as finance chief at the firm since 2019, is leaving Teladoc to pursue an opportunity outside the healthcare sector, according to a press release. Alongside the leadership news, Teladoc released prelimin ...

Exhibit 99.1 Teladoc Health Announces Chief Financial Officer Transition Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaf irms Full-Year 2025 Consolidated Outlook "It has been a privilege to serve as Teladoc Health's Chief Financial Officer during a pivotal time in virtual care," said Murthy. "I'm deeply grateful for the opportunity to have worked with such an exceptional, committed team." In conjunction with this leadership announcement, Teladoc Health reaffirmed its 2025 full-y ...

Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated OutlookNEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunity outside of the healthcare industry. Ms. Murthy will continue to serve in her role until her departure on November 21, 2025 and will present on the company’s third qua ...

文章核心观点 - 文章探讨两家表现不佳的医疗保健公司Iovance Biotherapeutics和Teladoc Health的投资潜力 并分析哪一家是更具吸引力的逆向投资选择 [1][2] - 尽管两家公司均面临挑战且具有高风险 但文章认为Teladoc Health是目前更好的选择 因其收入更高 亏损更低 且拥有更深的生态系统和品牌知名度 [13][16] Iovance Biotherapeutics分析 - Iovance Biotherapeutics是一家小型生物技术公司 其开发的Amtagvi是首个获批用于晚期黑色素瘤的疗法 [3] - 自2024年2月获批以来 Amtagvi销售额逐步增长 2025年上半年公司收入达1.093亿美元 较去年同期增长超过三倍 [3] - 公司预计本财年收入在2.5亿至3亿美元之间 当前市值仅为7.73亿美元 [4] - Amtagvi近期在加拿大获批 并计划在其他国家推出 公司估计美国每年有8000名患者死于黑色素瘤 潜在市场巨大 [4][5] - 该药物正在被研究用于治疗其他类型癌症 若取得临床和监管进展 有望推动公司盈利 [6] - Amtagvi的生产和管理复杂 需使用患者自身细胞 平均耗时34天制造 并通过静脉输注给药 且只能在专业中心进行 这限制了药物的可及性并增加了商业化成本 [6][7] Teladoc Health分析 - Teladoc Health是远程医疗市场的重要参与者 但其过去几年失去了显著的市场吸引力 [8] - 截至第二季度 其综合护理部门拥有1.024亿会员 较去年同期增长11% [8] - 公司的BetterHelp虚拟治疗部门正在流失付费用户 但公司已采取措施应对 包括收购虚拟心理健康服务提供商UpLift [9] - BetterHelp不包含保险覆盖 而UpLift与第三方支付方签订了覆盖1亿潜在患者的协议 这有助于吸引更多用户 [9][10] - 公司正通过国际扩张努力扭转局面 近期国际销售额增长较快 [10] - 第二季度总收入同比下降2% 至6.319亿美元 但公司在远程医疗市场的稳固地位 以及推动虚拟治疗业务和国际扩张的努力 可能助其复苏 [11][12] 投资比较与结论 - Teladoc Health目前是更好的选择 因其产生更高的收入 净亏损较低 并拥有深厚的生态系统和行业内的品牌知名度 [13] - Iovance Biotherapeutics的Amtagvi前景看似乐观 但药物的复杂性使其商业可行性存疑 若其具有商业价值 考虑到公司过去18个月股价表现不佳且市值低于10亿美元 可能已有大型制药公司进行收购 [15] - 对于风险承受能力高于平均水平的逆向投资者 应考虑选择Teladoc Health [16]

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2025 results on Wednesday, October 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 609817. For international participants, ...

Teladoc (TDOC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TDOC crossed above the 20-day moving average, suggesting a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.The ...

技术分析 - 公司股价已达到关键支撑位并突破了200日移动平均线 表明长期看涨趋势 [1] - 过去四周内公司股价已上涨13.5% 可能处于新一轮上涨的边缘 [2] 基本面与市场预期 - 公司当前为Zacks排名第一的股票 评级为强力买入 [2] - 当前财年盈利预测呈现积极修正 过去两个月内无任何预测被下调 且有一项预测被上调 共识预期也有所提高 [2] 综合投资观点 - 鉴于公司关键的技术面表现和积极的盈利预测修正 其近期可能获得更多涨幅 [3]

Key Takeaways TDOC adds workplace safety tools to its Clarity platform using AI video and audio analysis.The new feature detects threats and sends real-time alerts to hospital care teams for swift intervention.TDOC plans initial rollout of the safety tool with select hospitals in Q1 2026 to address staff safety issues.Teladoc Health, Inc. (TDOC) recently introduced a solution that will form part of the company’s Clarity monitoring platform.  Initially designed for use cases such as virtual patient sitting, ...